Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- Morgan Stanley -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (11)	10/16/2002 1:02:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 31

Harr was previously at Robbie Stephens....... 11/19/00........ thestreet.com So far, however, investors have mostly shied away from the dozen or so cancer vaccine companies including Avax, Progenics (PGNX:Nasdaq - news), Genzyme Molecular Oncology (GZMO:Nasdaq - news), Antigenics (AGEN:Nasdaq - news), Corixa (CRXA:Nasdaq - news), Dendreon (DNDN:Nasdaq - news) and others, causing shares in those vaccine makers to slide amid a surge in other kinds of biotechs. The companies missed the recent strong showing in biotech stocks, which have been the Nasdaq's top performers for much of the year. Blue Skies? "These stocks remain very cheap," says Steve Harr, analyst with Robertson Stephens, who recommends that investors buy a basket of stocks, since there will be winners and losers.